Design of Anti-Bacterial Drug and Anti-Mycobacterial Drug for Drug Delivery System

Author(s): Katsunori Yanagihara

Journal Name: Current Pharmaceutical Design

Volume 8 , Issue 6 , 2002

Become EABM
Become Reviewer


Liposome-encapsulated drugs often exhibit reduced toxicity and have also been shown to enhance retention of drugs in the tissues. Thus, encapsulation of drugs in liposomes has often resulted in an improved overall therapeutic efficacy. The results of efficacy of liposome-encapsulated ciplofloxacin or azithromycin for therapy of intracellular M. avium infection show enhanced cellular delivery of liposome-encapsulated antibiotics and suggest that efficiency of intracellular targeting is sufficient to mediate enhanced antimycobacterial effects. The antitubercular drugs encapsulated in lung specific stealth liposomes have enhanced efficacies against tuberculosis infection in mice. These results from stealth liposome study indicate that antitubercular drugs encapsulated in liposome may provide therapeutic advantages over the existing chemotherapeutic regimen for tuberculosis. Liposomes with encapsulated amikacin are able to protect collagen almost completely from adherence of bacterial cells of all strains examined and prevent from invading of bacteria.

Keywords: anti-bacterial drug, anti-mycobacterial drug, mycobacterium avium infection, mycobacterium tuberculosis infection, staphylococcus aureus infection, pseudomonas aeruginosa

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [475 - 482]
Pages: 8
DOI: 10.2174/1381612023395808
Price: $65

Article Metrics

PDF: 4